The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Open accessAbstract
Given its critical role in T-cell signaling, interleukin-2-inducible kinase (ITK) is an appealing therapeutic target that can contribute to the pathogenesis of certain infectious, autoimmune, and neoplastic diseases. Ablation of ITK subverts Th2 immunity, thereby potentiating Th1-based immune responses. While small-molecule ITK inhibitors have been identified, none have demonstrated clinical utility. Ibrutinib is a confirmed irreversible inhibitor of Bruton tyrosine kinase (BTK) with outstanding clinical activity and tolerability in B-cell malignancies. Significant homology between BTK and ITK alongside in silico docking studies support ibrutinib as an immunomodulatory inhibitor of both ITK and BTK. Our comprehensive molecular and phenotypic analysis confirms ITK as an irreversible T-cell target of ibrutinib. Using ibrutinib clinical trial samples along with well-characterized neoplastic (chronic lymphocytic leukemia), parasitic infection (Leishmania major), and infectious disease (Listeria monocytogenes) models, we establish ibrutinib as a clinically relevant and physiologically potent ITK inhibitor with broad therapeutic utility. This trial was registered at www.clinicaltrials.gov as #NCT01105247 and #NCT01217749.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although ibrutinib inhibits other similar kinases that contain C481, including ITK and BLK,7,22”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At relapse, none of the patients had mutations in other kinases containing a cysteine residue homologous to C481 in BTK that are irreversibly inhibited by ibrutinib”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“mutations have not been observed in these other targets, findings that suggest that BTK is its critical target.”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Self-citationAdvani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 1×
“Irreversible ITK binding, ITK signal inhibition, and Th1-skewed cytokine patterns were also identified in CLL patients treated with ibrutinib in 2 clinical trials.(37,38) These findings were validated using a well-established mouse model of cutaneous leishmaniasis, and further clinical relevance was demonstrated using…”
BackgroundSelf-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citationLong-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome
Kim, Y. H., Liu, H. L., Mraz‐Gernhard, S., Varghese, A., & Hoppe, R. T. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.7.857 · Cited by 652
Ramsay, A. G., Johnson, A. J., Lee, A. M., Görgün, G., Dieu, R. L., Blum, W. G., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 619
Self-citationMarks, D. I., Paietta, E. M., Moorman, A. V., Richards, S. M., Buck, G. A. N., Dewald, G. W., Ferrando, A. A., Fielding, A. K., Goldstone, A. H., Ketterling, R. P., et al. (2009) · Blood · doi:10.1182/blood-2009-08-231217 · Cited by 420
The B-cell receptor signaling pathway as a therapeutic target in CLL
Woyach, J. A., Johnson, A. J., & Byrd, J. C. (2012) · Blood · doi:10.1182/blood-2012-02-362624 · Cited by 412
Self-citationRequirement for Tec Kinases Rlk and Itk in T Cell Receptor Signaling and Immunity
Schaeffer, E. M., Debnath, J., Yap, G. S., McVicar, D. W., Liao, X. C., Littman, D. R., Sher, A., VARMUS, H. E., Lenardo, M. J., & Schwartzberg, P. L. (1999) · Science · doi:10.1126/science.284.5414.638 · Cited by 398
TEC FAMILY KINASES IN T LYMPHOCYTE DEVELOPMENT AND FUNCTION
Berg, L. J., Finkelstein, L. D., Lucas, J. A., & Schwartzberg, P. L. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104743 · Cited by 341
Liu, K., Bunnell, S. C., Gurniak, C. B., & Berg, L. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.10.1721 · Cited by 337
Cited by
Sorted by citations
Items 301–400 of 813
Jebaraj, B. M. C., Müller, A., Dheenadayalan, R. P., Endres, S., Roessner, P. M., Seyfried, F., Walliser, C., Wist, M., Qi, J., Tausch, E., et al. (2021) · Blood · doi:10.1182/blood.2021011516 · Cited by 28
Mancuso, S., Mattana, M., Carlisi, M., Santoro, M., & Siragusa, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063368 · Cited by 27
Xiao, X., Wang, Y., Zou, Z., Yang, Y., Wang, X., Xin, X., Tu, S., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954235 · Cited by 28
Ibrutinib-A double-edge sword in cancer and autoimmune disorders
Kokhaei, P., Jadidi‐Niaragh, F., Jahromi, A. S., Österborg, A., Mellstedt, H., & Hojjat‐Farsangi, M. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1086357 · Cited by 27
Repurposing of gastric cancer drugs against COVID-19
Sonkar, C., Doharey, P. K., Rathore, A. S., Singh, V. K., Kashyap, D., Sahoo, A. K., Mittal, N., Sharma, B., & Jha, H. C. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104826 · Cited by 27
Biomarkers for acute and chronic graft versus host disease: state of the art
Giaccone, L., Faraci, D., Butera, S., Lia, G., Vito, C. D., Gabrielli, G., Cerrano, M., Mariotti, J., Dellacasa, C. M., Felicetti, F., et al. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2021.1860001 · Cited by 26
BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review
Stack, M., Sacco, K. A., Castagnoli, R., Livinski, A. A., Notarangelo, L. D., & Lionakis, M. S. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108816 · Cited by 27
Targeting Solid Tumors With BTK Inhibitors
Uckun, F. M., & Venkatachalam, T. K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650414 · Cited by 26
Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma
Alcantara, M., Fuentealba, J. R., & Soussain, C. (2021) · Cancers · doi:10.3390/cancers13205061 · Cited by 27
Schmid, V., & Hobeika, E. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1339620 · Cited by 27
Rushworth, S. A., Pillinger, G., Abdul-Aziz, A. M., Piddock, R. E., Shafat, M. S., Murray, M. Y., Zaitseva, L., Lawes, M. J., MacEwan, D. J., & Bowles, K. M. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00046-0 · Cited by 26
Tuijnenburg, P., de Kerk, D. J. A., Jansen, M. H., Morris, B., Lieftink, C., Beijersbergen, R. L., van Leeuwen, E. M. M., & Kuijpers, T. W. (2019) · European Journal of Immunology · doi:10.1002/eji.201948241 · Cited by 26
Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review
Metzler, J. M., Burla, L., Fink, D. A., & Imesch, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114154 · Cited by 26
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities
Vardi, A., Vlachonikola, E., Papazoglou, D., Psomopoulos, F. E., Kotta, K., Ioannou, N., Galigalidou, C., Gemenetzi, K., Pasentsis, K., Kotouza, M. T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3827 · Cited by 26
Epstein–Barr Virus in Inborn Immunodeficiency—More Than Infection
Lino, C. N. R., & Ghosh, S. (2021) · Cancers · doi:10.3390/cancers13194752 · Cited by 28
Zhu, Z., Luo, Y., Lou, G., Yihunie, K. D., Wizzard, S., DeVilbiss, A., Muh, S., Ma, C., Shinde, S. S., Hoar, J., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adk2954 · Cited by 25
Beielstein, A. C., & Pallasch, C. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174158 · Cited by 26
Stock, S., Kluever, A.-K., Endres, S., & Kobold, S. (2022) · Biomedicines · doi:10.3390/biomedicines10020307 · Cited by 25
Bačová, B., Kohutová, Z., Zubata, I. K., Gahérová, Ľ., Kučera, P., Heizer, T., Mikesova, M., Karel, T., & Novák, J. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00809-0 · Cited by 26
Therapeutic benefits targeting B-cells in chronic graft-versus-host disease
Nakasone, H., Sahaf, B., & Miklos, D. B. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1782-4 · Cited by 25
Schliffke, S., Akyüz, N., Ford, C. T., Mährle, T., Thenhausen, T., Krohn-Grimberghe, A., Knop, S. T., Bokemeyer, C., & Binder, M. (2016) · Leukemia · doi:10.1038/leu.2016.157 · Cited by 25
Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia
Cubillos‐Zapata, C., Ortiz, J. A., Córdoba, R., Hernández-Jiménez, E., Toledano, V., de Diego, R. P., & López‐Collazo, E. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1242544 · Cited by 25
Boi, M., Todaro, M., Vurchio, V., Yang, S. N., Moon, J. H., Kwee, I., Rinaldi, A., Pan, H., Crescenzo, R., Cheng, M. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12876 · Cited by 25
Hepatitis B reactivation in patients receiving targeted therapies
Chang, C., Tsai, C., & Yan, S. (2017) · Hematology · doi:10.1080/10245332.2017.1321882 · Cited by 25
SLAMF6 in health and disease: Implications for therapeutic targeting
Yigit, B., Wang, N., Herzog, R. W., & Terhorst, C. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.10.013 · Cited by 24
Abramson, J. S., Lunning, M. A., & Palomba, M. L. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238693 · Cited by 24
An update on novel therapeutic intervention in Rheumatoid arthritis
Shah, P., Siddique, A., Thakkar, A. P., Gharat, S., Godad, A. P., Kale, P. P., & Doshi, G. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108794 · Cited by 24
Complex interactions of cellular players in chronic Graft-versus-Host Disease
Gail, L. M., Schell, K. J., Łacina, P., Strobl, J., Bolton, S. J., Ulriksen, E. S., Bogunia‐Kubik, K., Greinix, H., Crossland, R. E., Inngjerdingen, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1199422 · Cited by 26
Maseda, D., Bonami, R. H., & Crofford, L. J. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.907744 · Cited by 24
Molica, S., & Polliack, A. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.09.002 · Cited by 24
Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma
Kumar, A. A., Vardhana, S. A., Moskowitz, A. J., Porcu, P., Doǧan, A., Dubovsky, J. A., Matasar, M. J., Zhang, Z., Younes, A., & Horwitz, S. M. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017011916 · Cited by 25
Self-citationBenner, B. N., Scarberry, L., Stiff, A. R., Duggan, M. C., Good, L., Lapurga, G., Butchar, J. P., Tridandapani, S., & Carson, W. E. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1659704 · Cited by 25
Arthur, R., Valle‐Argos, B., Steele, A. J., & Packham, G. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00009 · Cited by 24
Shchegravina, E. S., Svirshchevskaya, E. V., Combes, S., Allegro, D., Barbier, P., Gigant, B., Varela, P. F., Gavryushin, A. E., Kobanova, D. A., Shchekotikhin, A. E., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112724 · Cited by 24
Mulder, T. A., Peña‐Pérez, L., Berglöf, A., Meinke, S., Estupiñan, H. Y., Heimersson, K., Zain, R., Månsson, R., Smith, C. I. E., & Palma, M. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000564 · Cited by 24
Misbah, S. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.12948 · Cited by 23
Pagano, L., & Facchinelli, D. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.063 · Cited by 23
The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View
Tambaro, F. P., Novellis, D. D., & Wierda, W. G. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s265284 · Cited by 23
Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges
Perutelli, F., Jones, R., Griggio, V., Vitale, C., & Coscia, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837531 · Cited by 24
Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management
Baumrin, E., Loren, A. W., Falk, S. J., Mays, J. W., & Cowen, E. W. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2022.12.023 · Cited by 23
RetractedXPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression
Fisher, J. G., Doyle, A. D. P., Graham, L. V., Sonar, S., Sale, B., Henderson, I., Rio, L. D., Johnson, P., Landesman, Y., Cragg, M. S., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01984-z · Cited by 23
Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia
Maharaj, K. K., Sahakian, E., & Pinilla-Ibarz, J. A. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017006809 · Cited by 23
Byrd, J. C., Ruppert, A. S., Heerema, N. A., Halvorson, A. E., Hoke, E. E., Smith, M. R., Godwin, J. E., Couban, S., Fehniger, T. A., Thirman, M. J., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017015396 · Cited by 23
Self-citationThe effect of ibrutinib on neutrophil and γδ T cell functions
Risnik, D., Elías, E. E., Keitelman, I. A., Colado, A., Podaza, E., Cordini, G., Rubio, M. V., Grecco, H. F., Bezares, R. F., Borge, M., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1753043 · Cited by 23
Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis
Lafleur, A., Daffis, S., Mowbray, C. E., & Arana, B. A. (2024) · Vaccines · doi:10.3390/vaccines12101179 · Cited by 22
Estupiñan, H. Y., Bouderlique, T., He, C., Berglöf, A., Gupta, D., Saher, O., Cruz, M. Á. D., Peña‐Pérez, L., Yu, L., Zain, R., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001319 · Cited by 22
Lin, A. Y., Cuttica, M. J., Ison, M. G., & Gordon, L. I. (2020) · eJHaem · doi:10.1002/jha2.98 · Cited by 22
Can, İ., Cox, M. J., Siegler, E. L., Sakemura, R. L., & Kenderian, S. S. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.02.001 · Cited by 23
Papazoglou, D., Wang, V., Shanafelt, T. D., Lesnick, C. E., Ioannou, N., Rossi, G. D., Herter, S., Bacac, M., Klein, C., Tallman, M. S., et al. (2023) · Blood · doi:10.1182/blood.2023020554 · Cited by 22
Molica, S., Levato, L., & Mirabelli, R. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1071489 · Cited by 22
The B-Cell Receptor Pathway: A Critical Component of Healthy and Malignant Immune Biology
Zhong, Y., Byrd, J. C., & Dubovsky, J. A. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.05.007 · Cited by 22
Self-citationImmune Checkpoint Inhibition in Hodgkin Lymphoma
Moy, R. H., & Younes, A. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000020 · Cited by 22
Chu, Y., Lee, S., Shah, T., Yin, C., Barth, M. J., Miles, R. R., Ayello, J. S., Morris, E., Harrison, L., van de Ven, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1512455 · Cited by 22
Definition of the Chemical and Immunological Signals Involved in Drug-Induced Liver Injury
Ali, S.-E., Waddington, J. C., Park, B. K., & Meng, X. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00275 · Cited by 22
Creeden, J. F., Alganem, K., Imami, A. S., Henkel, N., Brunicardi, F. C., Liu, S., Shukla, R., Tomar, T., Naji, F., & McCullumsmith, R. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228823 · Cited by 22
Hofland, T., de Weerdt, I., ter Burg, H., de Boer, R., Tannheimer, S., Tonino, S. H., Kater, A. P., & Eldering, E. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900321 · Cited by 21
Cryptococcosis Associated With Biologic Therapy: A Narrative Review
Li, X., Paccoud, O., Chan, K. H., Yuen, K., Manchon, R., Lanternier, F., Slavin, M. A., van de Veerdonk, F. L., Bicanic, T. A., & Lortholary, O. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae316 · Cited by 21
Ahmed, N., Kambhampati, S., Hamadani, M., Hu, Z., Grover, N. S., Shadman, M. S., Locke, F. L., Gerson, J. N., Frank, M. J., Budde, L. E., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015014 · Cited by 21
Novel Treatments for Chronic Lymphocytic Leukemia and Moving Forward
Brown, J. R., Porter, D. L., & O'Brien, S. M. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e317 · Cited by 22
Mulvey, J. J., Nuovo, G. J., & MAGRO, C. M. J. (2016) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000441 · Cited by 21
Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia
Itchaki, G., & Brown, J. R. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717741861 · Cited by 23
BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
Munoz, J. L., Wang, Y., Jain, P., & Wang, M. L. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01286-0 · Cited by 21
Noto, A., Cassin, R., Mattiello, V., Bortolotti, M., Reda, G., & Barcellini, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1062376 · Cited by 21
Rotin, L. E., Gronda, M., MacLean, N., Hurren, R., Wang, X., Lin, F.-H., Wrana, J. L., Datti, A., Barber, D. L., Minden, M. D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6409 · Cited by 22
Cavazzini, F., Lista, E., Quaglia, F. M., Formigaro, L., Cavallari, M., Martinelli, S., Rigolin, G. M., Foà, R., & Cuneo, A. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2016.1154955 · Cited by 21
Ibrutinib and fungus: an invasive concern
Rogers, K. A. (2018) · Blood · doi:10.1182/blood-2018-02-832154 · Cited by 21
Ibrutinib in CLL/SLL: From bench to bedside (Review)
Zi, F., Li, Y., Shi, Q., Tang, A., & Cheng, J. (2019) · Oncology Reports · doi:10.3892/or.2019.7364 · Cited by 21
Hodkinson, B. P., Schäffer, M., Brody, J., Jurczak, W. J., Carpio, C. D. C., Ben‐Yehuda, D., Avivi, I. M., Forslund, A., Özcan, M., Alvarez, J. D., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100977 · Cited by 24
Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
Kueffer, L. E., Joseph, R. E., & Andreotti, A. H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.655489 · Cited by 22
Lv, L., Sun, X., Wu, Y., Cui, Q., Chen, Y., & Liu, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.707285 · Cited by 21
Woyach, J. A. (2015) · Hematology · doi:10.1182/asheducation-2015.1.355 · Cited by 20
Self-citationBond, D. A., & Maddocks, K. J. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.06.007 · Cited by 20
Self-citationMartinez-Hernandez, J. E., Hammoud, Z., de Sousa, A. M., Krämer, F., do Monte‐Neto, R. L., Maracaja‐Coutinho, V., & Martín, A. J. M. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01018-21 · Cited by 20
Krug, A., Tari, G., Saidane, A., Gaulard, P., Ricci, J., Lemonnier, F., & Verhoeyen, E. (2022) · Cancers · doi:10.3390/cancers14102392 · Cited by 22
Moreno, C., Solman, I. G., Tam, C. S. L., Grigg, A., Scarfò, L., Kipps, T. J., Srinivasan, S. S., Mali, R. S., Zhou, C., Dean, J. P., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010236 · Cited by 20
Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy
Peres, C., Matos, A. I., Carreira, B., Moura, L. I. F., Kleiner, R., Vaskovich‐Koubi, D., Reshef, K., Dulberg, S., Verdial, M., Conniot, J., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202401749 · Cited by 20
Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia
Wang, S., Ebert, T., Jaekel, N., Schubert, S., Niederwieser, D. W., & Al‐Ali, H. K. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2385-0 · Cited by 20
Hutchinson, C. V., & Dyer, M. J. S. (2014) · British Journal of Haematology · doi:10.1111/bjh.12895 · Cited by 21
Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders
Phillips, T. J., Devata, S., & Wilcox, R. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0201-6 · Cited by 21
Ibrutinib-Induced Neutrophilic Dermatosis
Halabi, L. E., Cherif-Rebai, K., Michot, J., & Ghez, D. (2017) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000862 · Cited by 20
Non‐Aspergillus invasive mould infections in patients treated with ibrutinib
Anastasopoulou, A. N., DiPippo, A. J., & Kontoyiannis, D. P. (2020) · Mycoses · doi:10.1111/myc.13120 · Cited by 20
Mohty, R., & Gauthier, J. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01420-9 · Cited by 20
Infante, M. S., Fernández‐Cruz, A., Núñez, L., Carpio, C. D. C., Ubieto, A. J., López‐Jiménez, J., Vásquez, L., Campo, R. D., Romero, S., Alonso, C., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4293 · Cited by 20
Duarte‐Sanmiguel, S., Panic, A., Dodd, D. J., Salazar‐Puerta, A. I., Moore, J. T., Lawrence, W. R., Nairon, K. G., Francis, C., Zachariah, N., McCoy, W., et al. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101619 · Cited by 20
Drug repurposing to treat asthma and allergic disorders: Progress and prospects
Kruse, R. L., & Vanijcharoenkarn, K. (2017) · Allergy · doi:10.1111/all.13305 · Cited by 20
Palma, M., Krstic, A., Peña‐Pérez, L., Berglöf, A., Meinke, S., Wang, Q., Blomberg, K. E. M., Kamali‐Moghaddam, M., Shen, Q., Jaremko, G., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15516 · Cited by 20
Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy
Grover, N. S., & Park, S. I. (2015) · Pharmaceuticals · doi:10.3390/ph8030607 · Cited by 19
Ibrutinib and Indolent B-Cell Lymphomas
Akinleye, A., Furqan, M., & Adekunle, O. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.11.005 · Cited by 19
Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia
Edelmann, J., & Gribben, J. G. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.023291 · Cited by 19
Huang, Y., Chen, L., Tang, Z., Yu, M., Yu, W., Yang, G., & Zhang, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.774244 · Cited by 19
Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis
Nocco, S. E., Andriano, T. M., Bose, A., Chilov, M., Godwin, K., Dranitsaris, G., Wu, S., Lacouture, M. E., Roeker, L. E., Mato, A. R., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103696 · Cited by 21
Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
Liu, Y., Song, Y., & Yin, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.962552 · Cited by 22
The Role of Surgical Pathology in Guiding Cancer Immunotherapy
Lovitch, S. B., & Rodig, S. J. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044125 · Cited by 19
Colado, A., Almejún, M. B., Podaza, E., Risnik, D., Stanganelli, C., Elías, E. E., Santos, P. D., Slavutsky, I. R., Grecco, H. F., Cabrejo, M., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1946-y · Cited by 19
Is HBV prophylaxis required during CLL treatment with ibrutinib?
Tedeschi, A., Frustaci, A. M., Mazzucchelli, M., Cairoli, R., & Montillo, M. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1317094 · Cited by 19
Targeting B Cell Signaling in Chronic Lymphocytic Leukemia
Arnason, J. E., & Brown, J. R. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0620-7 · Cited by 19
Jacobson, C. A., & Maus, M. V. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003391 · Cited by 20
Jacobs, C. F., Eldering, E., & Kater, A. P. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003768 · Cited by 19
Analysis of Genetic Host Response Risk Factors in Severe COVID-19 PatientsPreprint
Taylor, K., Das, S., Pearson, M. W., Kozubek, J. A., Pawłowski, M., Jensen, C. E., Skowron, Z., Møller, G. L., Strivens, M. A., & Gardner, S. (2020) · medRxiv · doi:10.1101/2020.06.17.20134015 · Cited by 19
Recent advances in therapy of chronic lymphocytic leukaemia
Routledge, D. J. M., & Bloor, A. J. C. (2016) · British Journal of Haematology · doi:10.1111/bjh.14184 · Cited by 18
Metadata
- Authors
- Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., Stefanovski, M. R., Chappell, D. L., Frissora, F. W., Smith, L. L., Smucker, K. A., Flynn, J. M., Jones, J. A., Andritsos, L. A., Maddocks, K., Lehman, A. M., Furman, R., Sharman, J., Mishra, A., Caligiuri, M. A., Satoskar, A. R., Buggy, J. J., Muthusamy, N., Johnson, A. J., & Byrd, J. C.
- Affiliations
- Department of Internal Medicine, Division of Hematology,
- The Ohio State University (US)
- Pharmacyclics (United States) (US)
- Weill Cornell Medicine (US)
- Willamette Valley Cancer Institute and Research Center (US)
- Department of Pathology, and
- ORCID
- Beckwith, Kyle A.
- Natarajan, Gayathri
- Woyach, Jennifer A.
- Jaglowski, Samantha
- Chang, Betty Y.
- Chappell, Danielle L.
- Smith, Lisa L.
- Flynn, Joseph M.
- Jones, Jeffrey A.
- Andritsos, Leslie A.
- Maddocks, Kami
- Furman, Richard
- Sharman, Jeff
- Mishra, Anjali
- Caligiuri, Michael A.
- Satoskar, Abhay R.
- Muthusamy, Natarajan
- Johnson, Amy J.
- Byrd, John C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-10-10
- Volume
- 122
- Issue
- 15
- Pages
- 2539-2549
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3795457
- OpenAlex
- W2089103836
- Cited by
- 810
- References
- 49
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 55 · 2023: 51 · 2022: 70 · 2021: 98 · 2020: 68 · 2019: 71 · 2018: 71 · 2017: 70 · 2016: 65 · 2015: 67 · 2014: 43 · 2013: 5
- FWCI
- 29.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (4p01ca081534-16)
- National Cancer Institute (P01CA095426, P50CA140158, T32CA009338, 5 T32 CA009338-33-03, P30CA016058, K12CA133250, P01-CA-081534)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- ibrutinib, irreversible kinase inhibitors, Bruton's tyrosine kinase, T cell signaling, Th1 response, Th2 immune response, chronic lymphocytic leukemia, Leishmania major, Listeria monocytogenes, immunomodulation
- MeSH terms
- Adenine, Animals, Disease Models, Animal, Enzyme Inhibitors, Humans, Leukemia, Listeriosis, Lymphocyte Activation, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Leishmaniasis, Cutaneous, CD8-Positive T-Lymphocytes, Th1 Cells, Th2 Cells, Jurkat Cells, Mice, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
